The present disclosure relates to the development of novel immunoassays for the detection of SARS-CoV-2 or secreted spike protein (or fragments thereof) in saliva, nasal mucosal sample, throat samples, or nasopharyngeal samples.

An immunoassay platform and methodology are described for discriminatively detecting target microorganism antibodies to a target antigen in a biological sample derived from a host animal, from among antibodies of cross-reactively-related microorganism(s) potentially present in the biological sample, by use of contemporaneous assays conducted with and without blocking antibodies exogenous to the host animal. Attenuation of detection reagent signal between the contemporaneous assays may be used to determine a target antigen previously infected or non-infected status of the host animal. An assay system is described, including: a single-use cartridge containing test strips constituted to perform the immunoassay; an integrated sample collection and processing device engageable with the single-use cartridge for delivery of sample thereto, and for operatively initiating immunoassay performance in the single-use cartridge; and a portable immunoassay reader for reading immunoassay output signals from the test strips of the single-use cartridge.

A sensor for the rapid, onsite identification of analytes characterized by: (a) a sample layer; (b) at least one reaction layer, interconnected with the sample layer; (c) at least one reporter layer, interconnected with the reaction payer; (d) at least one preventative layer, interconnected with the reporter layer; and (e) an absorption pad, interconnected with the preventative layer; with the layers arranged as a signaling channel.

A method of diagnosing, staging or monitoring cancer, the method comprising the steps of: (a) providing a sensor array comprising at least two sensors, wherein each sensor comprises a protein barrel that comprises five or more alpha helices arranged as an alpha-helical barrel, and a reporter dye, wherein the protein barrel defines a lumen, the reporter dye is bound to the lumen reversibly; and wherein the protein barrel is different in structure in the at least two sensors; (b) contacting the sensor array with a sample obtained from a patient; and then (c) comparing the sensor array to a predetermined standard.

A microdevice includes a plurality of calibration curve liquids, a plurality of first microchannels respectively filled with the plurality of calibration curve liquids, at least one second microchannel filled with a measurement target liquid, and a sealing member that closes openings of the first microchannels to seal the calibration curve liquids. Each of the calibration curve liquids includes a measurement target substance of a predetermined concentration, the predetermined concentration in each of the plurality of calibration curve liquid being mutually different, an antibody that specifically binds to the measurement target substance, and a fluorescent-labeling derivative that fluorescently labels the measurement target substance and competes with the measurement target substance to specifically bind to the antibody. The measurement target liquid includes an unknown concentration of the measurement target substance, the antibody, and the fluorescent-labeling derivative.

The present invention relates to a method for detecting and in particular for measuring C-peptide. Specifically, the present invention relates to a displacement assay for quantitative determination of C-peptide in a sample.

The present invention relates to a method and reagents for determining the presence of or the amount of an analyte in a sample.

The present application relates to an assay method using affinity crosslinking of DNA-linked ligands to proteins to enable small molecule screening and determination of apparent affinity constants of ligands to the proteins. This method has been applied to determine 96 compounds' dissociation constants to a protein target simultaneously, and directly determine a compound's IC.sub.50 against five protein targets concurrently in crude cell lysates. Additionally, this approach was used to screen a Library of Pharmacologically Active Compounds (LOPAC) library against dihydrofolate reductase (eDHFR), enabling the discovery of a novel eDHFR inhibitor (IC50=7.9 μM). An assay kit and the method of uses are within the scope of this disclosure.

Described herein, are methods of detecting neutralizing antibodies that bind to Clostridioides difficile (C. diff) toxin B (TcdB), prognosing the disease severity of Clostridioides difficile infection (CDI) and the risk of primary and recurrent CDI, as well as providing a guide for clinical practice. Also described herein are kits for performing the methods of this disclosure.

An immunoassay platform and methodology are described for discriminatively detecting target microorganism antibodies to a target antigen in a biological sample derived from a host animal, from among antibodies of cross-reactively-related microorganism(s) potentially present in the biological sample, by use of contemporaneous assays conducted with and without blocking antibodies exogenous to the host animal. Attenuation of detection reagent signal between the contemporaneous assays may be used to determine a target antigen previously infected or non-infected status of the host animal. An assay system is described, including: a single-use cartridge containing test strips constituted to perform the immunoassay; an integrated sample collection and processing device engageable with the single-use cartridge for delivery of sample thereto, and for operatively initiating immunoassay performance in the single-use cartridge; and a portable immunoassay reader for reading immunoassay output signals from the test strips of the single-use cartridge.